Showing 491 - 500 of 578
Persistent link: https://www.econbiz.de/10008882205
Persistent link: https://www.econbiz.de/10008882233
Persistent link: https://www.econbiz.de/10008314447
Persistent link: https://www.econbiz.de/10008314475
In this chapter we study a team dynamic problem in which a group of agents collaborate over time to complete a project. The project progresses at a rate that depends on the agents' efforts, and it generates a payoff upon completion. First, we show that agents work harder the closer the project...
Persistent link: https://www.econbiz.de/10012999755
This paper maps out different research strands by using thematic analysis on the literature pertaining to large companies' efforts on social sustainability in their supply chains. The data corpus for this thematic analysis is a broad sample of the literature with articles from different journals...
Persistent link: https://www.econbiz.de/10012946479
In many developing countries, governments often use Minimum support prices (MSPs) as interventions to (i) safeguard farmers' income against crop price falls, and (ii) ensure sufficient and balanced production of different crops. In this paper, we examine two questions: (1) What is the impact of...
Persistent link: https://www.econbiz.de/10012949213
We take a business analytic approach to examine ways to reduce environmental incidents committed by Chinese manufacturers. We first perform descriptive analysis to examine the long-term impact of environmental incidents on a firm's performance that is measured in terms of Returns On Assets...
Persistent link: https://www.econbiz.de/10012913443
This forum paper examines the past and the future of Operations Management (OM) research.First, we investigate the evolution of OM research from 1997 to 2018 by using machine learning tools to analyze all OM papers published in five journals (JOM, MS, M&SOM, POM, and OR), and find that the...
Persistent link: https://www.econbiz.de/10012846790
There are more than 7,000 known rare diseases, but pharmaceutical manufacturers developed treatments for only 500 of them. To improve the availability and accessibility of treatments for rare diseases, governments have introduced several programs including subsidies, innovative pricing schemes,...
Persistent link: https://www.econbiz.de/10012846957